BASSEM ZRAIK: Open Payments
NPI 1548542491 · CLEVELAND, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$986 in 50 payments from 16 companies in 2025. Trend: 2023 $279 · 2024 $995 · 2025 $986
Food & beverage: $944Education: $43
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 14 | $251 |
| Lilly USA, LLC | 10 | $149 |
| Mannkind Corporation | 3 | $91 |
| Otsuka America Pharmaceutical, Inc. | 3 | $77 |
| AstraZeneca Pharmaceuticals LP | 3 | $67 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $61 |
| ABBVIE INC. | 2 | $49 |
| Axsome Therapeutics, Inc. | 2 | $44 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $38 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $37 |
Products named: HETLIOZ, AFREZZA, FANAPT, REXULTI, Kerendia, MOUNJARO, VRAYLAR, Auvelity.
Industry payments across OH — which companies pay providers there.
